The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify
1Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK. Philip.Johnson@liverpool.ac.uk.
2School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
3Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.
4Public Health Scotland, Glasgow, UK.
5Department of Health Data Science, University of Liverpool, Liverpool, UK.
6Computational Biology Facility, University of Liverpool, Liverpool, UK.
7Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
8Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
Abstract
Background and aims: The aMAP score is a model that predicts risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis. Its performance in a 'real world' surveillance setting has not yet been ascertained.
Patients and methods: We had access to a cohort of 3473 individuals enrolled in a rigorously implemented and prospectively accrued surveillance programme (patients undergoing regular ultrasound and biomarker examination between 1998 and 2021). During this period 445 had HCC detected. Of these, 77.8% had early stage disease (within Milan criteria), permitting potentially curative therapy to be implemented in nearly 70% of cases. We applied the recently developed aMAP score to classify patients according to their initial aMAP score in to low, medium and high-risk groups as proposed in the original publication. The performance of the aMAP score was assessed according to the concordance-index and calibration (i.e. agreement between observed and predicted risk). Allowance was made for competing causes of death.
Results: The aMAP score achieved an overall C-index of 0.81 (95% CI: 0.79-0.82) consistent with the initial report and was unaffected by allowance for competing causes of death. Sub-group analysis showed that the results did not change significantly according to gender, or aetiology. However, aMAP discrimination was greater for younger individuals (versus older individuals), and also for individuals without cirrhosis. The HCC incidence rate was 0.98, 7.05 and 29.1 events per 1000 person-years in the low-, moderate- and high-risk aMAP groups, respectively.
Conclusions: The results from this 'real-world' cohort demonstrate that risk stratification is a realistic prospect and that identification of a subgroup of chronic liver disease patients who have a very low risk of HCC is feasible.